Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Trial Profile

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs NAV 5001 (Primary)
  • Indications Parkinson's disease
  • Focus Diagnostic use; Registrational
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 12 Sep 2016 Status changed from active, no longer recruiting to discontinued.
    • 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.
    • 29 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top